您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Danoprevir(ITMN191,R7227 RO5190591 RG7227)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Danoprevir(ITMN191,R7227 RO5190591 RG7227)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Danoprevir(ITMN191,R7227 RO5190591 RG7227)图片
CAS NO:850876-88-9
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
Danoprevir (formerly ITMN-191, R-7227; RO-5190591; RG 7227; RG-7227; trade name Ganovo) is an orally bioavailable and 15-membered macrocyclic peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50s in the range of 0.2-3.5 nM. HCV NS3/4A protease represents an excellent target for anti-HCV drugs due to its involvement in viral replication and suppressive effects on host response to viral infection. Danoprevir was developed and marketed by Ascletis in China.
理化性质和储存条件
Molecular Weight (MW)731.83
FormulaC35H46FN5O9S
CAS No.850876-88-9
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 144 mg/mL (196.8 mM)
Water: <1 mg/mL
Ethanol: 144 mg/mL (196.8 mM)
Other info

Chemical Name: (2R,13aS,14aR,16aS,Z)-6-((tert-butoxycarbonyl)amino)-14a-((cyclopropylsulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoroisoindoline-2-carboxylate

InChi Key: ZVTDLPBHTSMEJZ-QIFYYAQYSA-N

InChi Code: InChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)/b11-7-/t22-,23-,27?,28+,35-/m1/s1

SMILES Code: O=C(N1CC2=C(C(F)=CC=C2)C1)O[C@@H](C3)C[C@](C(N[C@@](C4)(C(NS(=O)(C5CC5)=O)=O)[C@]4([H])/C=C\CCCCCC6NC(OC(C)(C)C)=O)=O)([H])N3C6=O

Synonymtrade name Ganovo; ITMN-191; RG 7227; ITMN 191; RO5190591; RG7227; RG-7227; ITMN191; RO-5190591; RO 5190591.
实验参考方法
In Vitro

In vitro activity: Danoprevir (0.29 nM) inhibits the reference genotype 1 NS3/4A protease half-maximally, but a high dose of Danoprevir (10 μM) shows no appreciably inhibition in a panel of 79 proteases, ion channels, transporters, and cell surface receptors. Danoprevir remains bound to and inhibits NS3/4A for more than 5 hours after its initial association. Danoprevir (45 nM) eliminates a patient-derived HCV genotype 1b replicon from hepatocyte-derived Huh7 cells with an EC50 of 1.8 nM. In HCV subgenomic replicon cell lines containing the individual mutations, V36M, R109K, and V170A substitutions confer little or no resistance to Danoprevir, but the R155K substitution confers a high level (62-fold increase) of resistance to Danoprevir. In Huh7.5 cells transfected with chimeric recombinant virus, Danoprevir shows antiviral inhibition effects against HCV genotypes 1, 4 and 6 with IC50 of 2-3 nM, which are>100-fold lower than genotypes 2/3/5 (280-750 nM).


Kinase Assay: The assay buffer contains 25 μM NS4A peptide, 50 mM Tris-HCl, pH 7.5, 15% (vol/vol) glycerol, 0.6 mM lauryldimethylamine N-oxide, 10 mM dithiothreitol, and 0.5 μM fluorescein/QXL520-labeled FRET substrate {Ac-DE-Dap(QXL520)-EE-Abu-ψ-[COO]-AS-Cys(5-FAMsp)-NH2}. K2040 enzyme (50 pM) is added to initiate the reaction. Reactions are set up in black 96-well plates, and fluorescence data is collected. Control reactions lacking inhibitors and enzyme are included. Initial rates are calculated from the linear phase of the reaction (up to 1 hour) and are used to obtain IC50. Recovery of activity from preformed Danoprevir-NS3/4A complex is assessed by preincubating 10 nM NS3/4A with a two-fold excess of Danoprevir in 1× assay buffer for 15 min, followed by a rapid 200-fold dilution of the preformed complex into assay buffer containing substrate. A control reaction with the same final conditions without preincubation of NS3/4A and Danoprevir is initiated by the addition of enzyme to an otherwise-complete reaction mixture. Additional control reactions lack either Danoprevir or NS3. The progress of the reactions is followed over 5 hours.


Cell Assay: Serially diluted Danoprevir is added to Huh7 cells harboring the K2040 replicon 1 day after cell plating. For antiviral assays, after a 48-hour incubation, intracellular RNA is extracted, and the level of HCV replicon RNA is quantified by reverse transcription (RT)-PCR assay with the primers (5'-CACTCCCCTGTGAGGAACTACTG-3' and 5'-AGGCTGCACGACACTCATACT-3') and a probe (5'-6-FAM-CTTCACGCAGAAAGCGTCTAGCCATGG-MGBNFQ-3' using an ABI Prism 7900 sequence detection system. Here, FAM is 6-carboxyfluorescin and MGBNFQ is a molecular-groove binding non-fluorescence quencher specific to the HCV 5' untranslated region. Single-tube reactions are performed using the TaqMan Gold RT-PCR kit. Triplicate reactions for the RNA standards and samples are performed in 50 μL with 5 μL intracellular RNA (50 ng). RT is carried out at 48 °C for 30 min followed by 10 min at 95 °C. The PCR is run as follows: 15 seconds at 95 °C and 1 min at 60 °C for 40 cycles. Each RNA concentration is determined in triplicate. The absolute concentration of replicon RNA is calculated based on its signal relative to that of a standard curve generated by known concentrations of an in vitro-transcribed RNA corresponding to a genotype 1b 5' untranslated region. Replicon levels in the presence of Danoprevir are fitted to a four-parameter logistic function to obtain EC50.

In VivoDanoprevir (30 mg/kg) administered to rats or monkeys shows that its concentrations in liver 12 hours after dosing exceed the Danoprevir concentration required to eliminate replicon RNA from cells.
Animal modelSprague-Dawley rats, Cynomolgus monkeys
Formulation & DosageDissolved in water. 6 mg/mL for rats and 3 mg/mL for monkeys; 30 mg/kg; P.O.
References

Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41; J Infect Dis. 2008 Sep 15;198(6):800-7.

生物活性

Progress curves describing biochemical inhibition of full-length NS3/4A. Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41.

Protease activity following dilution of preformed ITMN-191·NS3/4A complex. Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41.

Antiviral activity in combination with peginterferon alfa-2a. Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41.

Antiviral activity in combination with peginterferon alfa-2a. Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41.

Plasma and liver exposures of ITMN-191. The concentrations of ITMN-191 in liver and plasma were determined by liquid chromatography-tandem mass spectrometry following administration of a single oral dose of 30 mg/kg of ITMN-191 as an aqueous solution. Antimicrob Agents Chemother. 2008 Dec;52(12):4432-41.